Prelude Therapeutics Inc Ordinary Shares PRLD
News
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers